Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sunshine Lake Pharma Co., Ltd.
This phase IB trial is studying how well giving gemcitabine together with Z650 works in treating patients with metastatic or recurrent pancreatic cancer.This phase IB trial is Multi-center and open。
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
18 ≤ age ≤ 75 years old, male or female is not limited; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Life expectancy of ≥ 12 weeks Pathologically confirmed advanced pancreatic cancer defined as non-operable in a curative intent, locally recurrent, or metastatic disease.
You may not be if
adjuvant treatment with gemcitabine within 6 months prior to the first dose; Radiotherapy and anti-cancer Chinese patent medicine treatment were performed within 4 weeks before the first dose; Gastrointestinal diseases that could affect the absorption of Z650, (e.g., serious swallowing obstruction, chronic diarrhea, bowel obstruction); Doppler ultrasound evaluation of Left ventricular ejection fraction \< 50%
Clareo Health | Gemcitabine and Z650 in Treating Patients With Metastatic or Recurrent Pancreatic Cancer
